Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | PRKCA | P17252 | 3/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22921248 | 0.94 | CA1 (0.41) | CA1CA9CYP1A2PRKCATNKS | |
| SCHEMBL5585129 | 0.94 | CA1 (0.41) | CA1CA9CYP1A2PRKCATNKS | |
| SCHEMBL14131263 | 0.85 | — | — | |
| SCHEMBL1107367 | 0.85 | — | — | |
| SCHEMBL14131228 | 0.85 | — | — | |
| SCHEMBL14968783 | 0.82 | CA1 (0.34) | CA1CA9 | |
| SCHEMBL28481690 | 0.82 | CA1 (0.37) | CA1CA9CA2CA4KMT2A | |
| SCHEMBL8151656 | 0.80 | CA1 (0.34) | CA1CA9CA2CA4TSHR | |
| SCHEMBL20799724 | 0.76 | CA1 (0.38) | CA1CA9ALDH1A1CYP1A2PRKCA | |
| Lactic Acid SCHEMBL7156907 | 0.76 | TP53 (0.34) | CA1CA9KMT2ATSHRPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1803204-A | Absorbable biological medicinal membrane | CHENGDU ORGANIC CHEMICALS CO (CN) | 2006-07-19 | — | — | CN | claimed |
| WO-1995011927-A1 | POLYESTER-MODIFIED POLYDIENE/ACRYLOURETHANE OLIGOMERS | LORD CORPORATION (US) | 1995-05-04 | — | — | WO | claimed |
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | LAIRD ELLEN | 2009-07-09 | — | — | US | disclosed |
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | LAIRD ELLEN | 2009-07-09 | — | — | US | disclosed |
| US-7491829-B2 | RAF inhibitor compounds and methods | ARRAY BIOPHARMA INC. (US) | 2009-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176809-A1 | RAF INHIBITOR COMPOUNDS AND METHODS | BRAF, RAF1, ARAF | CA1 3950/4885CA9 4117/4885CA2 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.